

STEP THERAPY CRITERIA

DRUG CLASS	ATYPICAL ANTIPSYCHOTICS (BRAND ONLY PRODUCTS)
BRAND NAME (generic)	ABILIFY (ORAL TABLET & ORAL SOLUTION ONLY) (BRAND ONLY) (aripiprazole)
	ABILIFY MYCITE (BRAND ONLY) (aripiprazole)
	CAPLYTA (BRAND ONLY) (lumateperone)
	FANAPT (BRAND ONLY) (iloperidone)
	GEODON (ORAL CAPSULE) (BRAND ONLY) (ziprasidone)
	INVEGA (ORAL TABLET) (BRAND ONLY) (paliperidone)
	LATUDA (BRAND ONLY) (lurasidone hydrochloride)
	REXULTI (BRAND ONLY) (brexpiprazole)
	RISPERDAL (BRAND ONLY) (risperidone)
	SAPHRIS (BRAND ONLY) (asenapine)
	SECUADO (BRAND ONLY) (asenapine transdermal)
	SEROQUEL, SEROQUEL XR (BRAND ONLY) (quetiapine)
	VRAYLAR (BRAND ONLY)

(cariprazine)

ZYPREXA (BRAND ONLY)

(olanzapine)

Status: CVS Caremark Criteria

Type: Initial Step Therapy; Post Step Therapy Prior Authorization

Policy

FDA-APPROVED INDICATIONS

Abilify

Abilify Oral Tablets and Oral Solution are indicated for the treatment of:

- Schizophrenia
- Acute Treatment of Manic and Mixed Episodes associated with Bipolar I Disorder
- Adjunctive Treatment of Major Depressive Disorder
- Irritability Associated with Autistic Disorder
- Treatment of Tourette's Disorder

Abilify Mycite

Abilify Mycite, a drug-device combination product comprised of aripiprazole tablets embedded with an Ingestible Event Marker (IEM) sensor intended to track drug ingestion, is indicated for the treatment of:

- Adults with schizophrenia
- Treatment of bipolar I disorder
 - Acute treatment of adults with manic and mixed episodes as monotherapy and as adjunct to lithium or valproate
 - Maintenance treatment of adults as monotherapy and as adjunct to lithium or valproate
- Adjunctive treatment of adults with Major Depressive Disorder

Limitations of Use

The ability of the Abilify Mycite to improve patient compliance or modify aripiprazole dosage has not been established. The use of Abilify Mycite to track drug ingestion in "real-time" or during an emergency is not recommended because detection may be delayed or not occur.

Caplyta

Caplyta is indicated for the treatment of schizophrenia in adults.

Fanapt

Fanapt tablets are indicated for the treatment of adults with schizophrenia. Efficacy was established in two short-term (4- and 6-week) placebo- and active-controlled studies of adult patients with schizophrenia. When deciding among the alternative treatments available for this condition, the prescriber should consider the finding that Fanapt is associated with prolongation of the QTc interval. Prolongation of the QTc interval is associated in some other drugs with the ability to cause torsade de pointes-type arrhythmia, a potentially fatal polymorphic ventricular tachycardia which can result in sudden death. In many cases this would lead to the conclusion that other drugs should be tried first. Whether Fanapt will cause torsade de pointes or increase the rate of sudden death is not yet known. Patients must be titrated to an effective dose of Fanapt. Thus, control of symptoms may be delayed during the first 1 to 2 weeks of treatment compared to some other antipsychotic drugs that do not require a similar titration. Prescribers should be mindful of this delay when selecting an antipsychotic drug for the treatment of schizophrenia. The effectiveness of Fanapt in long-term use, that is, for more than 6 weeks, has not been systematically evaluated in controlled trials. Therefore, the physician who elects to use Fanapt for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient.

Geodon

Geodon is indicated for the treatment of schizophrenia, as monotherapy for the acute treatment of Bipolar manic or mixed episodes, and as an adjunct to lithium or valproate for the maintenance treatment of Bipolar disorder. Geodon intramuscular is indicated for acute agitation in schizophrenic patients. When deciding among the alternative treatments available for the condition needing treatment, the prescriber should consider the finding of ziprasidone's greater capacity to prolong the QT/QTc interval compared to several other antipsychotic drugs. Prolongation of the QTc interval is associated in some other drugs with the ability to cause torsade de pointes-type arrhythmia, a potentially fatal polymorphic ventricular tachycardia, and sudden death. In many cases this would lead to the conclusion that other drugs should be tried first. Whether ziprasidone will cause torsade de pointes or increase the rate of sudden death is not yet known.

Schizophrenia

Geodon is indicated for the treatment of schizophrenia. The efficacy of oral ziprasidone was established in four short-term (4-week and 6-week) controlled trials of adult schizophrenic inpatients and in one maintenance trial of stable adult schizophrenic inpatients.

Bipolar I Disorder

Geodon is indicated as monotherapy for the acute treatment of manic or mixed episodes associated with Bipolar I disorder. Efficacy was established in two 3-week monotherapy studies in adult patients.

Geodon is indicated as an adjunct to lithium or valproate for the maintenance treatment of Bipolar I disorder. Efficacy was established in a maintenance trial in adult patients. The efficacy of Geodon as monotherapy for the maintenance treatment of Bipolar I disorder has not been systematically evaluated in controlled clinical trials.

Acute Treatment of Agitation in Schizophrenia

Geodon intramuscular is indicated for the treatment of acute agitation in schizophrenic patients for whom treatment with ziprasidone is appropriate and who need intramuscular antipsychotic medication for rapid control of agitation. The efficacy of intramuscular ziprasidone for acute agitation in schizophrenia was established in single day controlled trials of agitated schizophrenic inpatients. "Psychomotor agitation" is defined in DSM-IV as "excessive motor activity associated with a feeling of inner tension." Schizophrenic patients experiencing agitation often manifest behaviors that interfere with their diagnosis and care, e.g., threatening behaviors, escalating or urgently distressing behavior, or self-exhausting behavior, leading clinicians to the use of intramuscular antipsychotic medications to achieve immediate control of the agitation.

Since there is no experience regarding the safety of administering ziprasidone intramuscular to schizophrenic patients already taking oral ziprasidone, the practice of co-administration is not recommended.

Ziprasidone intramuscular is intended for intramuscular use only and should not be administered intravenously.

Invega

Schizophrenia

Invega (paliperidone) Extended-Release Tablets are indicated for the treatment of schizophrenia. The efficacy of Invega in schizophrenia was established in three 6-week trials in adults and one 6-week trial in adolescents, as well as one maintenance trial in adults.

Schizoaffective Disorder

Invega (paliperidone) Extended-Release Tablets are indicated for the treatment of schizoaffective disorder as monotherapy and an adjunct to mood stabilizers and/or antidepressant therapy. The efficacy of Invega in schizoaffective disorder was established in two 6-week trials in adults.

Latuda

Latuda is indicated for:

- Treatment of adult and adolescent patients age 13 to 17 years with schizophrenia
- Monotherapy treatment of adult and pediatric patients (10 to 17 years) with major depressive episodes associated with Bipolar I disorder (bipolar depression)
- Adjunctive treatment with lithium or valproate in adult patients with major depressive episodes associated with Bipolar I disorder (bipolar depression)

Rexulti

Rexulti is indicated for:

- Adjunctive treatment of major depressive disorder (MDD)
- Treatment of schizophrenia

Risperdal

Risperdal is indicated for:

- Treatment of schizophrenia
- Monotherapy or adjunctive therapy with lithium or valproate, for the treatment of acute manic or mixed episodes associated with Bipolar I Disorder
- Treatment of irritability associated with autistic disorder

Saphris

Saphris is indicated for:

- Schizophrenia in adults
- Bipolar I disorder
 - Acute monotherapy of manic or mixed episodes, in adults and pediatric patients 10 to 17 years of age
 - Adjunctive treatment to lithium or valproate in adults
 - Maintenance monotherapy treatment in adults

Secuado

Secuado is indicated for the treatment of adults with schizophrenia

Seroquel

Schizophrenia

Seroquel is indicated for the treatment of schizophrenia. The efficacy of Seroquel in schizophrenia was established in three 6-week trials in adults and one 6-week trial in adolescents (13–17 years). The effectiveness of Seroquel for the maintenance treatment of schizophrenia has not been systematically evaluated in controlled clinical trials.

Bipolar Disorder

Seroquel is indicated for the acute treatment of manic episodes associated with Bipolar I disorder, both as monotherapy and as an adjunct to lithium or divalproex. Efficacy was established in two 12-week monotherapy trials in adults, in one 3-week adjunctive trial in adults, and in one 3-week monotherapy trial in pediatric patients (10-17 years).

Seroquel is indicated as monotherapy for the acute treatment of depressive episodes associated with Bipolar disorder. Efficacy was established in two 8-week monotherapy trials in adult patients with Bipolar I and Bipolar II disorder.

Seroquel is indicated for the maintenance treatment of Bipolar I disorder, as an adjunct to lithium or divalproex. Efficacy was established in two maintenance trials in adults. The effectiveness of Seroquel as monotherapy for the maintenance treatment of Bipolar disorder has not been systematically evaluated in controlled clinical trials.

Special Considerations in Treating Pediatric Schizophrenia and Bipolar I Disorder

Pediatric schizophrenia and Bipolar I disorder are serious mental disorders, however, diagnosis can be challenging. For pediatric schizophrenia, symptom profiles can be variable, and for Bipolar I disorder, patients may have variable patterns of periodicity of manic or mixed symptoms. It is recommended that medication therapy for pediatric schizophrenia and Bipolar I disorder be initiated only after a thorough diagnostic evaluation has been performed and careful consideration given to the risks associated with medication treatment. Medication treatment for both pediatric schizophrenia and Bipolar I disorder is indicated as part of a total treatment program that often includes psychological, educational and social interventions.

Seroquel XR

Schizophrenia

Seroquel XR is indicated for the treatment of schizophrenia. The efficacy of Seroquel XR in schizophrenia was established

in one 6-week and one maintenance trial in adults with schizophrenia. Efficacy was supported by three 6-week trials in adults with schizophrenia and one 6-week trial in adolescents with schizophrenia (13-17 years) treated with Seroquel.

Bipolar Disorder

Seroquel XR is indicated for the acute treatment of manic or mixed episodes associated with Bipolar I disorder, both as monotherapy and as an adjunct to lithium or divalproex. The efficacy of Seroquel XR in manic or mixed episodes of Bipolar

I disorder was established in one 3-week trial in adults with manic or mixed episodes associated with Bipolar I disorder. Efficacy was supported by two 12-week monotherapy trials and one 3-week adjunctive trial in adults with manic episodes associated with Bipolar I disorder as well as one 3-week monotherapy trial in children and adolescents (10-17 years) with manic episodes associated with Bipolar I disorder treated with Seroquel.

Seroquel XR is indicated for the acute treatment of depressive episodes associated with Bipolar disorder. The efficacy of Seroquel XR was established in one 8-week trial in adults with Bipolar I or II disorder and supported by two 8-week trials in adults with Bipolar I or II disorder treated with Seroquel.

Seroquel XR is indicated for the maintenance treatment of Bipolar I disorder, as an adjunct to lithium or divalproex. Efficacy was extrapolated from two maintenance trials in adults with Bipolar I disorder treated with Seroquel. The effectiveness of monotherapy for the maintenance treatment of Bipolar I disorder has not been systematically evaluated in controlled clinical trials.

Adjunctive Treatment of Major Depressive Disorder (MDD)

Seroquel XR is indicated for use as adjunctive therapy to antidepressants for the treatment of MDD. The efficacy of Seroquel XR as adjunctive therapy to antidepressants in MDD was established in two 6-week trials in adults with MDD who had an inadequate response to antidepressant treatment.

Special Considerations in Treating Pediatric Schizophrenia and Bipolar I Disorder

Pediatric schizophrenia and Bipolar I disorder are serious mental disorders, however, diagnosis can be challenging. For pediatric schizophrenia, symptom profiles can be variable, and for Bipolar I disorder, patients may have variable patterns of periodicity of manic or mixed symptoms. It is recommended that medication therapy for pediatric schizophrenia and Bipolar I disorder be initiated only after a thorough diagnostic evaluation has been performed and careful consideration given to the risks associated with medication treatment. Medication treatment for both pediatric schizophrenia and Bipolar I disorder is indicated as part of a total treatment program that often includes psychological, educational and social interventions.

Vraylar

Vraylar is indicated for:

- Treatment of schizophrenia in adults
- Acute treatment of manic or mixed episodes associated with bipolar I disorder in adults
- Treatment of depressive episodes associated with bipolar I disorder (bipolar depression) in adults

Zyprexa

Zyprexa is indicated for:

- Treatment of schizophrenia
- Acute treatment of manic or mixed episodes associated with bipolar I disorder and maintenance treatment of bipolar I disorder
- Adjunct to valproate or lithium in the treatment of manic or mixed episodes associated with bipolar I disorder

INITIAL STEP THERAPY

If the patient has filled a prescription for at least a 30 day supply of generic aripiprazole, olanzapine, paliperidone, quetiapine, quetiapine extended release, risperidone, or ziprasidone within the past 180 days under a prescription benefit administered by CVS Caremark, then the requested drug will be paid under that prescription benefit. If the patient does not meet the initial step therapy criteria, then the claim will reject with a message indicating that a prior authorization (PA) is required. The prior authorization criteria would then be applied to requests submitted for evaluation to the PA unit.

COVERAGE CRITERIA

The requested drug will be covered with prior authorization when the following criteria are met:

- The patient is currently taking the requested drug with evidence of improvement
OR
- The patient has experienced an inadequate treatment response after a trial of at least 30 days to one of the following generic products: A) aripiprazole, B) olanzapine, C) paliperidone, D) quetiapine, E) quetiapine extended release, F) risperidone, G) ziprasidone
OR
- The patient has an intolerance or contraindication that would prohibit a 30 day trial to one of the following generic products: A) aripiprazole, B) olanzapine, C) paliperidone, D) quetiapine, E) quetiapine extended release, F) risperidone, G) ziprasidone
OR
- The patient has a clinical condition for which there is no generic alternative or the generic alternatives are not recommended based on published guidelines or clinical literature

REFERENCES

1. Abilify [package insert]. Rockville, MD: Otsuka America Pharmaceutical, Inc.; February 2020.
2. Abilify Mycite [package insert]. Rockville, MD: Otsuka America Pharmaceutical, Inc.; February 2020.
3. Caplyta [package insert]. New York, NY: Intra-Cellular Therapies, Inc.; December 2019
4. Fanapt [package insert]. Washington, DC: Vanda Pharmaceuticals; January 2016.
5. Geodon [package insert]. New York, NY: Pfizer/Roerig.; January 2020.
6. Invega [package insert]. Titusville, NJ: Janssen Pharmaceuticals, Inc.; July 2018.
7. Latuda [package insert]. Marlborough, MA: Sunovion Pharmaceuticals Inc.; December 2019.
8. Rexulti [package insert]. Rockville, MD: Otsuka America Pharmaceutical, Inc.; May 2019.
9. Risperdal [package insert]. Titusville, NJ: Janssen Pharmaceutical Ltd.; July 2018.
10. Saphris [package insert]. Irvine, CA: Allergan USA Inc.; February 2017.
11. Secuado [package insert]. Miami, Florida: Noven Therapeutics, LLC.; October 2019
12. Seroquel [package insert]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; January 2020.
13. Seroquel XR [package insert]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; January 2020.
14. Vraylar [package insert]. Madison, NJ: Allergan USA, Inc.; May 2019.
15. Zyprexa [package insert]. Indianapolis, IN: Eli Lilly and Company.; October 2019.
16. Lexicomp Online, AHFS DI (Adult and Pediatric) Online. Hudson, OH: Wolters Kluwer Clinical Drug Information, Inc. <http://online.lexi.com/>. Accessed March 2020.
17. Micromedex (electronic version). Truven Health Analytics, Greenwood Village, Colorado, USA. <http://www.micromedexsolutions.com/>. Accessed March 2020.
18. American Psychiatric Association. Practice guideline for the treatment of patients with schizophrenia. *Am J Psychiatry*. 2004; 161: (Suppl) 1-56. Available at: https://psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/schizophrenia.pdf. Accessed March 2020.
19. American Psychiatric Association. Practice Guideline for the treatment of patients with major depressive disorder, Third Edition. October 2010. Available at: https://psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/mdd.pdf. Accessed March 2020.
20. American Psychiatric Association. Practice Guideline for the treatment of patients with bipolar disorder, Second Edition. April 2002. Available at: https://psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/bipolar.pdf. Accessed March 2020.